This page shows the latest Article 50 news and features for those working in and with pharma, biotech and healthcare.
So weeks after the EU agreed an extension of Article 50 to 31 October – now just over 160 days away – there seems to have been little progress, despite appeals by President ... Number 10 had been informally saying that if the deals doesn’t get
50 years, warns a new report from charity the British Heart Foundation.
There’s little sign that the Brexit pressure will let up for a few months at least, now that a delay to the Article 50 date has been set to 31
With the extension of Article 50, we will work with Government to consider how best to prepare and review whether current plans for a no deal Brexit are still appropriate.”.
If ‘no-deal’ were rejected, Article 50 would be revoked and an inquiry set up to establish whether any form of Brexit could command a majority.
B ‘managed no-deal’ option with an extended transition period; accepting a no-deal exit on 12 April; revoking Article 50 and halting Brexit; and Common Market 2.0 – also known ... When it comes to any further extension to Article 50, which would be
More from news
Approximately 0 fully matching, plus 34 partially matching documents found.
killer question: ‘Should I stay or should I go?’ Our decision to trigger the employee equivalent of Article 50 will normally be influenced by our experiences with our current employer. ... We all know you. can’t run a business on 50% turnover, but
The goal that the WHO’s document set is to ‘gain worldwide commitment and action to reduce severe, avoidable medication-related harm by 50% in the next five years’. ... International research collaboration. In this article, we describe a programme
50 negotiations, which could result in a new Government with a different set of policy priorities and an alternative approach to Brexit. ... However, the Chancellor, Philip Hammond, welcomed the CBI’s call for an ‘indefinite’ transition period
How Brexit affects pharma. The British Government submitted Article 50 in March 2017, formerly giving giving notice its intent to leave the EU.
Notice under Article 50 was given at the end of March 2017, triggering the start of the two-year period during which the UK’s withdrawal from the EU will be
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need. ... That's why we have created this 50-question checklist to help you deliver an exceptional brand
The London based scientific communication studio have been named in this year’s Pharma Fast 50, an annual ranking of the UK’s fastest-growing companies within the pharmaceutical industry. ... For more on the Pharma Fast 50 read the full article: .
Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research Partnership
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...